Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy with endostatin and capecitabine for nasopharyngeal carcinoma after suboptimal induction chemotherapy
ChiCTR2400081969Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar and capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Three-year recurrence-free survival (RFS). Started Mar 2024; status: recruiting.
02
Drugs
endostarcapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2400081969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081969.